PTJ
CERE

Paul Tudor Jones’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Paul Tudor Jones’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-126,538
Closed -$5.17M – 3222
2024
Q2 		$5.17M Buy
126,538
+84,806
+203% +$3.53M 0.03% 648
2024
Q1 		$1.76M Buy
+41,732
New +$1.75M 0.01% 1081
2023
Q4 		– Sell
-79,450
Closed -$1.73M – 3007
2023
Q3 		$1.73M Buy
+79,450
New +$1.99M 0.02% 1003

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Paul Tudor Jones's CERE Position: Q3 2024 in Review

Paul Tudor Jones sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 126,538 shares — an estimated $5.17M sold.

Paul Tudor Jones first reported a position in CERE in Q3 2023 and held it in 3 quarters. The position peaked at $5.17M in Q2 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Paul Tudor Jones reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Paul Tudor Jones sold 126,538 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $5.17M.
  • Paul Tudor Jones first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q3 2023 and held it in 3 quarters.
  • Paul Tudor Jones's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $5.17M in Q2 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Tudor Investment Corp's 13F filing for Q3 2024, filed 14 Nov 2024.